Cargando…

CHA2DS2-VASc Is Associated With In-Hospital Mortality in Patients With Infective Endocarditis: A Cross-Sectional Cohort Study

Background and objective The CHA(2)DS(2)-VASc score is a stroke risk stratification tool that is used in patients with atrial fibrillation (AF). Most of its clinical variables have been associated with poor outcomes in patients with infective endocarditis (IE). In this study, we aimed to determine i...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Temidayo, De Allie, Gabrielle, Eyituoyo, Harry O, Abe, Tolulope, Tobun, Temitope, Asotibe, Jennifer C, Hayes, Dolphurs, Mather, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752800/
https://www.ncbi.nlm.nih.gov/pubmed/33364135
http://dx.doi.org/10.7759/cureus.11620
Descripción
Sumario:Background and objective The CHA(2)DS(2)-VASc score is a stroke risk stratification tool that is used in patients with atrial fibrillation (AF). Most of its clinical variables have been associated with poor outcomes in patients with infective endocarditis (IE). In this study, we aimed to determine its utility in predicting outcomes in IE patients. Methods We included 35,570 patients with IE from the National Inpatient Sample (NIS), 2009-2012. The CHA(2)DS(2)-VASc score was calculated for each patient. Hierarchical logistic regression was used to estimate the adjusted odds ratio for in-hospital mortality for CHA(2)DS(2)-VASc scores from 1 to 9, using a score of 0 as the reference score. All clinical characteristics were defined using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Results The mean age of the sample was 57.81 ±14 years. Higher CHA(2)DS(2)-VASc scores were associated with increased mortality, and the scores among the sample ranged from 0 for 8.1% to 8 for 21.7%. In the hierarchical logistic regression, after adjusting for age, sex, and relevant comorbidities, as the score increased, so did the odds for overall mortality. Conclusion In patients with IE, the CHA(2)DS(2)-VASc score may serve as a risk assessment tool with which to predict outcomes. Further studies are needed to replicate these findings.